Ipsen to acquire Akkadeas Pharma's primary care platform

Pharmaceutical Company Restructures

Ipsen has signed an agreement to acquire the primary care platform of Akkadeas Pharma in Italy.

The company will take an equity stake in Akkadeas Pharma, with an option to buy the business outright in the future. A privately-held Italian consumer healthcare company, Akkadeas Pharma has a diversified gastrointestinal-focused portfolio including probiotics, medical devices and food supplements.

“Ipsen has agreed a deal to purchase the primary care platform of Italy's Akkadeas Pharma.“

As part of the deal, Akkadeas Pharma has agreed to become Ipsen's distributor for the product Smecta in the Italian market, which represents an important component of its broader European business.

Jean Fabre, executive vice-president for primary care at Ipsen, said the move will help "to accelerate Ipsen's primary care business, bringing in an established commercial infrastructure to distribute Smecta and generate instant incremental revenue, with the potential to further leverage as the market develops".

This comes after the company agreed a deal to purchase a portfolio of oncology assets from Merrimack Pharmaceuticals earlier this month, giving it access to the multipurpose cancer therapy Onivyde, among other treatments.

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.

See all the latest jobs in Pharmaceutical
Return to news

Tags